Test Price
2,800 AED✅ Home Collection Available
CFB Gene Hemolytic Uremic Syndrome (aHUS) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين CFB لمتلازمة انحلال الدم اليوريمية (aHUS) بتقنية التسلسل الجيني من الجيل التالي في الإمارات | 2800 درهم | وفق إرشادات هيئة الصحة بدبي 2026
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited NGS Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain, and VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
ملخص تنفيذي
يوفر تحليل جين CFB بتقنية التسلسل الجيني المتقدم دقة تشخيصية تصل إلى 99.9%، مع خدمة سحب منزلي معتمدة واستشارة طبية بعد النتائج. نلتزم بقانون المرسوم الاتحادي رقم 41 لسنة 2024 وقانون البيانات الصحية لضمان خصوصية المريض وسلامته التشخيصية.
Test Overview
This Next-Generation Sequencing (NGS) test screens the entire CFB gene for pathogenic variants linked to complement factor B dysregulation, the primary driver of atypical Hemolytic Uremic Syndrome (aHUS) and related hepatorenal-endocrine disorders. It provides a definitive molecular diagnosis to guide targeted therapies and familial risk assessment.
يفحص هذا التحليل جين CFB كاملاً بتقنية التسلسل الجيني من الجيل التالي لتحديد الطفرات المسببة لمتلازمة انحلال الدم اليوريمية غير النمطية، مما يمكّن الأطباء من وضع خطة علاجية دقيقة وتقييم المخاطر العائلية.
| Feature | Our NGS Comprehensive Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | NGS (Whole Gene + Regulatory Regions) | Sanger (Targeted Exons Only) |
| Variant Detection | 99.9% Diagnostic Sensitivity, includes deep intronic variants | ~95% sensitivity, misses non-exonic variants |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Cost in UAE (AED) | 2,800 | 3,200 – 4,500 |
Physician Insight & Safety Protocol
"As a practicing clinician, I remind every patient that a genetic test result must be correlated with clinical symptoms, renal function, and complement biomarker levels. No single test replaces holistic specialist evaluation."
"If your result reveals a CFB variant, know that it offers a pathway to precision therapy – not a sentence. Multidisciplinary care involving nephrologists and clinical geneticists is paramount."
"For children, UAE law mandates explicit parental consent and pre-test genetic counseling. We prioritize safety and emotional wellbeing above all."
— Dr. Prabhakar Reddy, DHA License No.: 61713011
Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Genetic test outcomes should guide, not abruptly alter, ongoing therapy, especially immunosuppressants or complement inhibitors.
Safety Exclusion Criteria & ER Red Flags
- Exclusion: Patients unable to give informed consent; minors without legal guardian authorization as per UAE CDS Law 2026.
- Exclusion: Recent allogeneic blood transfusion (within 4 weeks) may interfere with germline DNA analysis.
- Emergency Red Flag: Sudden oliguria, severe pallor, petechiae, or altered mental status – signs of acute thrombotic microangiopathy require immediate ER care.
- Emergency Red Flag: Active hemolytic crisis with rapid hemoglobin drop – do not wait for genetic results; seek emergency nephrology consultation.
Patient FAQ & Clinical Guidance
Q: How accurate is CFB gene sequencing for diagnosing atypical HUS?
A: This NGS test delivers 99.9% diagnostic sensitivity by analyzing the complete CFB gene plus regulatory regions, far surpassing single-exon methods. It can identify both known and novel pathogenic variants critical for confirming aHUS.
س: ما مدى دقة تحليل جين CFB في تشخيص متلازمة انحلال الدم اليوريمية غير النمطية؟ ج: بدقة تصل إلى 99.9%، يحلل الفحص الجين بالكامل متضمناً المناطق التنظيمية، مما يتيح اكتشاف الطفرات المسببة للمرض.
Q: Do I need to stop any medications before the blood draw?
A: No medication discontinuation is required; this is a germline DNA test unaffected by most drugs. Continue all prescribed treatments unless your physician specifically advises otherwise after a clinical review.
س: هل يجب إيقاف أي أدوية قبل سحب العينة؟ ج: لا، لا حاجة لإيقاف الأدوية لأن الفحص يعتمد على الحمض النووي الوراثي ولا يتأثر بالعلاجات المعتادة.
Q: Can a CFB genetic test guide treatment after diagnosis?
A: Yes, identifying a CFB mutation confirms complement-mediated aHUS, making you eligible for anti-complement therapy (e.g., eculizumab/ravulizumab) and aids in transplant risk assessment.
س: هل يمكن لفحص جين CFB توجيه العلاج بعد التشخيص؟ ج: نعم، الطفرة المؤكدة تؤهل المريض لعلاجات مثبطة للمتممة مثل إيكوليزوماب وتساعد في تقييم مخاطر زراعة الكلى.
Clinical Intent & Specialist Mapping
This is designed for precise molecular diagnosis of complement factor B-related atypical HUS, distinguishing it from thrombotic thrombocytopenic purpura and STEC-HUS. Indicated for: Nephrologists (renal microangiopathy management), Clinical Geneticists (variant interpretation & family counseling), and Oncologists (chemotherapy-related aHUS suspicion).
Full compliance with Federal Decree-Law No. 41 of 2024 (Article 87: Medical Data Confidentiality), CDS Law 2026 (Genetic Testing in Minors), and UAE Personal Data Protection Law (PDPL).
Accredited Facility License: 9834453 | ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
Contact & WhatsApp: +971 54 548 8731 | Home Collection available 8 AM – 11 PM daily.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians